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Abstract: The rise in prevalence of autism spectrum disorders (ASD) is suggestive of a new etiology. 
Diagnostic substitution alone is unlikely to account for the increase, while genetic association with 
detoxification gene alleles points to an environmental contribution. Subtle structural anomalies in the 
ASD brain are widespread but limbic damage seems important for the development of behaviors 
diagnostic of ASD. The limbic brain is especially susceptible to environmental challenge: internal 
sensing, physiological feedback and neuroinflammatory processes may underlie this sensitivity to 
insult. Primary damage leading to ASD in later life is likely to take place in utero and/or in the 
immediate postnatal period. Despite evidence of heavy metal involvement, a causal connection may 
not yet be concluded because subjects exposed to metals tend to be exposed to other environmental 
agents. Because maternal minerals and lipids are supplied to the unborn child, historic toxic exposure 
of the mother may be pivotal. A two-hit combination of genetic susceptibility and environmental 
challenge is argued to underlie the rise in ASD. 
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INTRODUCTION 
 
  Autism spectrum disorder (ASD) case numbers 
have risen markedly. In London, prevalence is now 116 
children per 10,000
[1] while ASD rates in the USA 
approach 1% in younger age groups
[2]. Most cases are 
of moderate to high severity, with 53% requiring 
prescription medication and up to 75% in sub-85 IQ 
bracket
[2,3]. 
  There is no consensus regarding the cause of the 
increase in case numbers. Widening diagnostic criteria 
and diagnostic substitution could lead to subjects once 
not diagnosed in this category now being allocated to 
ASD. There was an apparent fall in mental retardation 
cases as ASD increased
[4]; this assertion was found to 
be incorrect
[5] and was withdrawn
[6]. A subsequent large 
survey ruled out concomitant decline in the separate 
categories of either mental retardation or speech and 
language disability, concluding that “these data do not 
support the hypothesis of diagnostic shifting”
[7]. This 
study also reported an increase in attention deficit 
disorder paralleling the rise in ASD. 
  Using identical diagnostic criteria, autism 
prevalence rose 10-fold over a decade in Olmsted 
County, Minnesota
[8]. Byrd and colleagues
[9] in 
California addressed and excluded many possible 
confounding issues (earlier age of diagnosis, 
broadening criteria, migration), pointing to a real rise. 
ASD rates also increased progressively when younger 
children were studied
[7,8,10-15]. 
  Systematic survey in Canada
[16] recorded a 10% 
annual increase, with highest rates (107 per 10,000) in 
the younger children. The figures are underestimates: 
special schools providing services for children with 
mental retardation (an important subset of ASD) were 
excluded from the survey. The authors suggested that 
changes in diagnostic criteria, with increased awareness 
and referral, contribute to the rise. This was disputed by 
Taylor
[17] who stated “diagnostic transfer is not the 
major explanation for the increased prevalence of 
autism”, concurring with Fombonne and colleagues
[16] 
who observed that the ASD rise is accompanied by an 
identical increase in the subset of strictly-defined 
autistic disorder where misclassification is unlikely. 
Both exclude vaccine effects including measles-mumps 
rubella (MMR) and thimerosal preservative as major 
causes of the rise in ASD. Nevertheless, environmental 
influences cannot be ruled out
[16]. 
  Indicators of a real rise in the prevalence of ASD 
have been reviewed, including the changing spectrum 
of impairments, apparent increases in twin concordance 
rates, and the decline in a specific genetic contribution 
(Fragile X) within the ASD population
[18]. It has not 
been possible, on the basis of the available data, to 
refute the rigorous conclusion that there has been a real 
rise in prevalence, dubbed “new phase autism”
[18], that Am. J. Biochem. & Biotech., 4 (2): 183-197, 2008 
 
  184
suggests environmental influences. There is as yet no 
body of evidence sufficient to reject the role of 
environmental agents
[19,20]. 
 
GENETIC AND BIOCHEMICAL MARKERS IN ASD 
 
  Up to 10% of ASD cases are associated with 
genetic abnormalities including the Fragile X 
expansion, mutations in genes causing tuberous 
sclerosis, and a further diversity of rare metabolic 
deficiencies (as reviewed
[21-23]), but in no case is the 
genetic or biochemical deficiency sufficient to cause 
ASD in all carriers, pointing to environmental factors. 
  Genetic predisposition to environmental toxicity is 
consistent with differential representation of alleles of 
detoxification genes in ASD subjects versus controls. 
These genes include methylene tetrahydrofolate 
reductase (MTHFR), reduced folate carrier (RFC), 
transcobalamin II (TCN2), catechol-O-
methyltransferase (COMT) and glutathione 
sulfotransferase GST-M1
[24,25]. Skew in allele 
frequencies for paraoxonase (an organophosphate 
detoxifying enzyme, PON1)
[26] and glyoxalase I 
(GLO1)
[27] in ASD is suggestive of chemical exposure, 
while bias of ferroportin (SLC40A1/SLC11A3) and 
metal-activated transcription factor (MTF1) alleles
[28] is 
consistent with heavy metal involvement. No genetic 
studies have been reported for prominent metal-
susceptibility enzymes delta-aminolevulinic acid 
dehydratase (ALAD), coproporphyrinogen oxidase 
(CPOX), and stannin (SNN). Bias in histocompatibility 
haplotypes
[29-33] may be indicative of exogenous 
infectious or inflammatory agents as contributory 
factors in autism. 
  Diminished supply of sulfur-containing amino 
acids in ASD may also affect susceptibility to 
environmental agents because these amino acids are 
critical for some detoxification reactions. Plasma 
methionine and cysteine were reduced by 39% and 20% 
respectively in ASD
[24]; these are principally derived 
from the diet and gastrointestinal abnormalities 
(common in ASD) could be a contributing factor. The 
ratio of total reduced (GSH) to oxidized glutathione 
(GSSG) fell in ASD to ~50% of controls
[24,34], 
suggestive of oxidative stress. Abnormal metabolic 
markers in ASD include deficiencies of 
dehydroepiandrosterone (DHEA) and oxytocin
[35,36] and 
stochastic elevations of blood testosterone and 
cortisol
[37,38]. Disturbed steroid endocrinology is a 
known outcome of environmental toxicity
[39,40]. 
LIMBIC DAMAGE AND ASD 
 
  Structural studies on the ASD  brain (post-mortem  
or imaging)  have revealed a variety of changes that 
distinguish autistic from control subjects
[41-43]. The most 
consistent alterations are seen in the limbic brain, 
centered on the hippocampus, amygdala and adjoining 
brain regions, but with significant perturbations in 
cerebellum and cortex
[44,45].  
 
Limbic damage in ASD: Limbic/temporal lobe 
damage has been causally linked to ASD 
development
[46-51]. Subjects with early and selective 
damage to the hippocampus fulfilled ASD diagnostic 
criteria; Hauser et al.
[46] suggested that dysfunction of 
the medial temporal lobe is a major factor in the 
pathogenesis of infantile autism. Bilateral hippocampal 
dysfunction in early life is associated with a profound 
failure of cognitive capacities, including language 
learning and the acquisition of complex social and 
adaptive skills; these deficits correspond to the 
cognitive deficits of severe infantile autism
[52]. 
Abnormalities of the medial temporal lobes, 
encompassing the limbic hippocampal formation and 
amygdala, were argued to underlie the cognitive, 
perceptual and language impairments of ASD
[53], and 
this is supported by the known roles of the limbic brain 
in anxiety, memory, pain sensing and physiological 
regulation, all disturbed in ASD
[18].  
 
Abnormalities in other brain regions in ASD: 
Abnormalities are seen in many other areas of the 
autistic brain, often in cerebellum. The cerebellum is 
centrally involved in physical coordination and postural 
control. Although ataxia is sometimes seen in subjects 
with ASD, this is unlikely to relate to the social, 
linguistic and behavioral deficits of these disorders, and 
is likely to be an incidental accompaniment. Other brain 
regions with possible involvement in the pathoetiology 
of ASD include hypothalamic and brain-stem nuclei, 
but these have not been well studied. 
 
The deficits of autistic disorder are wider than 
limbic damage: The manifestations of ASD extend 
beyond the diagnostic triad to hyperactivity, brainwave 
abnormalities and frank seizure activity
[18,54], network 
and complex processing abnormalities
[55-57], weak 
central coherence
[58,59], underconnectivity
[60], and 
altered excitation/inhibition ratios
[61]. Sensory 
abnormalities are also common
[62]. Paradoxical 
responses include squinting, looking out of the corner 
of the eyes, gaze aversion, staring at the shadows of 
waving fingers
[63] and a fixation on the sense of Am. J. Biochem. & Biotech., 4 (2): 183-197, 2008 
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smell
[64]. These manifestations may be accompaniments 
to the primary damage that causes the diagnostic 
impairments of ASD.  
  
ENVIRONMENTAL SUSCEPTIBILITY AND 
THE LIMBIC BRAIN IN ASD 
 
  The limbic brain (hippocampus, amygdala and 
functionally related brain regions) is especially 
vulnerable to toxic insult. Agents causing specific 
damage to the hippocampus include bacterial 
toxins
[65,66], vitamin B1 deficiency
[67,68], excess 
homocysteine
[69,70], hepatic encephalopathy
[71]; copper 
deficiency
[72], glucocorticoid excess or deficiency
[73-75], 
ethanol exposure
[76], oxygen deprivation
[52,77] and 
irradiation
[78]. Limbic damage, particularly in the 
hippocampus, is the primary outcome of challenge, 
while other brain regions often largely retain their 
integrity. Nevertheless, other structures which 
potentially could be damaged (including the 
hypothalamus and brainstem) are difficult to study, and 
have been omitted from most screens, a significant 
limitation. 
  Toxic damage to the hippocampus is illustrated by 
exposure to trimethyl tin (TMT). From rats and mice to 
primates
[79,80] including humans
[81-84], systemic TMT 
exposure produces marked and selective destruction of 
the hippocampal dentate gyrus, with milder effects on 
hippocampal regions CA1-3, amygdala, subcortex, and 
cerebellum. TMT exposure thus causes selective 
damage in the same brain regions implicated in autism 
and ASD. TMT treatment of rats is reported to entrain 
an autism-like behavioral disorder
[85]. 
 
Dividing cells: The unusual fragility of the central 
formation of the limbic brain, the hippocampus, 
requires an explanation. Considerable attention has 
focused on one striking feature of the hippocampus - 
the presence of dividing cells in the formation. Because 
dividing cells are especially sensitive to toxic damage, 
it seems intuitive to suggest that this could underlie the 
vulnerability of the formation. Though relevant to 
restorative processes, it will be argued that ongoing cell 
division is unlikely to explain susceptibility of specific 
brain regions in relation to ASD development. 
  Neurogenesis takes place into adulthood in the 
dentate gyrus of rodents, monkeys
[86,87], and human
[88]. 
Some late production of new neurons continues in other 
brain regions, including the olfactory system, 
amygdala, temporal cortex and cerebellum
[89,90] but 
overall, late neurogenesis is principally restricted to the 
hippocampus (and olfactory system) in primates
[91,92]. 
Mitotic cells are exquisitely sensitive to chemical 
toxins, as exploited by anti-cancer therapy, and dentate 
damage is often seen in subjects receiving radiation or 
chemotherapeutic treatments. Dividing cells are also 
preferred substrates for viral replication: dentate 
destruction takes place in experimental animals infected 
with bornavirus
[93], and bornavirus infection has been 
proposed as an animal model of ASD
[94,95]. 
  Nevertheless, there is no one-to-one association 
between vulnerability to toxic insult and the presence of 
dividing cells. The type and location of limbic damage 
depends more on the nature of the insult than on the 
presence of dividing cells. Glucocorticoid excess and 
X-ray irradiation, like TMT, selectively cause loss of 
dentate granule neurons
[75,78,96]. In contrast, early 
ethanol exposure selectively reduces neuronal number 
in the dentate hilar region, and not in the granule cell 
layer
[76]. X-irradiation and chemotherapeutic agents 
cause loss of both subgranular progenitor cells and non-
dividing dentate hilar oligodendrocytes
[96-98]. The 
dentate gyrus can be unaffected - early beta and gamma 
irradiation reduces cell numbers in the CA1-3 
regions
[99,100] with additional damage in the cerebellum, 
but not in the dentate gyrus. Oxygen deprivation (as in 
cerebral ischemia) leaves the dentate intact but 
selectively destroys hippocampal CA region pyramidal 
neurons
[101,102] as seen in some ASD subjects
[52]. 
  While these studies confirm the regional 
vulnerability of the hippocampus, clearly the location 
and type of damage does not depend on the presence of 
dividing cells. Indeed, neurogenesis is widespread in 
the developing brain, and not just in limbic regions. 
While preferential susceptibility of dividing cells to 
viral replication may underlie the late development of 
ASD as a result of viral infection of the brain in 
adolescents and adults
[103,104] when neurogenesis is 
more restricted, other factors must underlie particular 
vulnerability of the limbic brain. 
 
Internal sensing: The hippocampus is unusually 
responsive to metabolic signals. Receptors and 
signalling molecules are strikingly abundant in the 
hippocampus
[105-109]. The hippocampus is a primary 
target for soluble ligands that reflect body physiology, 
including ion balance and blood pressure, immunity, 
pain, reproductive status, satiety and stress
[110]. 
Selective expression may reflect internal sensing 
(enteroception, also interoception) in the reciprocal 
accommodation of brain function, motivated behavior, 
and body physiology. Region-specific limbic damage is 
predicted if chemical insults aberrantly target receptors 
selectively expressed in the hippocampal formation. 
  This may explain selective hippocampal 
destruction by TMT. Stannin, a mitochondrial metal-
binding protein, is a prerequisite for TMT toxicity. In 
the absence of stannin, target cells are largely refractory 
to TMT
[111,112]. Stannin is most prominently expressed 
in the hippocampus
[113]. It is further induced by pro-Am. J. Biochem. & Biotech., 4 (2): 183-197, 2008 
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inflammatory cytokines
[114], relevant to inflammatory 
processes taking place in ASD. 
 
Blood-brain barrier: Intuitively, the tight junctions 
between epithelial cells in the brain microvasculature 
might direct environmental toxicity to regions that are 
unprotected. However, the functional development of 
the barrier is complex
[115,116]. Even in the adult, there is 
active transport of polypeptides, molecules, and ions 
from the blood into the brain. In neonates subjected to 
excess of the toxic pigment bilirubin (kernicterus: 
leading in some subjects to mental retardation and 
ataxia), the hippocampus is one of the areas stained 
selectively and hippocampal volume loss has been 
observed
[117]. The hippocampus (along with brain stem 
nuclei) seems to be particularly exposed to blood-borne 
substances. 
 
Physiological feedback: Peripheral insults also have a 
toxic inpact on the limbic brain, notably through the 
induction of neuroinflammation. Acting by vagal relay, 
systemic administration of inflammation-inducing 
lipopolysaccharide (LPS) or of interleukin IL-1 boosts 
the levels of neurotoxic pro-inflammatory cytokines in 
hippocampus and hypothalamus
[118,119]. Peripheral 
(respiratory) infection with Bordetalla pertussis or 
systemic administration of broken Shigella dysenteriae 
results in persistent hippocampal and hypothalamic 
expression of markers of inflammation including IL-1β 
and tumor necrosis factor (TNFα
[120,121]. Organometal 
(TMT) treatment of the post-natal mouse produces 
specific elevations in hippocampal pro-inflammatory 
cytokine mRNAs
[122,123]. 
  In ASD, striking increases in brain pro-
inflammatory cytokine molecules have been 
observed
[124,125]. The cause of ASD neuroinflammation 
has not been established, but peripheral inflammatory 
processes relay to the brain. Gut inflammation is 
common in autistic patients, notably with large excesses 
of particular Clostridial species
[126-128]. Gastrointestinal 
anomalies are frequent: in one study, 91% of ASD 
subjects were affected
[128]. Inflammatory processes 
taking place in gut, compounded by immune system 
deficiencies
[30,129-132] may contribute to brain 
inflammation in ASD.  
 
Oxidative stress: Local inflammation is associated 
with oxidative stress (OS); a role for this process in the 
pathoetiology of ASD has been proposed
[133-135]. 
Oxidative stress equates to interference with 
mitochondrial electron transport processes
[136], leading 
to the accumulation of reactive free radical species. 
Both LPS and TMT are potent inducers of oxidative 
stress in the brain
[137-140] as are other environmental 
agents such as the herbicide paraquat
[141] and heavy 
metals generally
[142-144]; the presumption is that these 
molecules cause mitochondrial damage, particularly in 
the vulnerable hippocampus. 
  Evidence for OS and mitochondrial damage in 
ASD includes attenuated GSH-GSSG ratios
[24,34] and 
excess urinary porphyrins
[145], the latter marks 
inhibition of heme synthesis of especial relevance to 
heme-dependent cytochromes and their key role in 
mitochondrial electron transfer. The most convincing 
demonstration of OS in autism disorders is the 
reproducible elevation of urinary isoprostanes
[146,147], a 
reliable marker of oxidative stress
[148]. Isoprostane 
elevation is also seen in methylmercury exposure
[149].  
 
ENVIRONMENTAL EXPOSURE IN ASD 
 
  ASD is typically diagnosed between two and four 
years of age, but retrospective analysis has revealed 
anomalies from earliest time-points. It seems likely, 
therefore, that prenatal or perinatal insult is pivotal, 
concurring with other strong evidence of major risk 
factors timed during gestation and the perinatal period. 
Early toxic exposure appears to be critical. Thalidomide 
exposure during gestation is a known risk factor for 
ASD development, but there is no evidence that 
thalidomide administered to older children (as an anti-
cancer agent) predisposes to autism disorders. 
Gestational exposure to anticonvulsant medication, 
tobacco, alcohol or cocaine, as well as to thalidomide, 
predisposes to ASD development in the child
[150-157]; 
exposure in later life appears to present no specific risk 
factor for the condition.  
 
Prenatal insults may include maternal infection: in 
an animal model, respiratory infection during 
pregnancy (but without fetal infection) was associated 
with later behavioral deficits in progeny reminiscent of 
autism
[158,159]. A role for prenatal injury associated with 
maternal psychosocial stress has been discussed
[160,161]; 
mild maternal stress in mice aggravates excitotoxic 
brain injury induced post-natally
[162]. 
 
Perinatal brain injury alone can predispose to ASD:  
Birth complications are generally more frequently 
recorded in subjects later diagnosed with 
ASD
[151,163,164]. Some rare ASD cases have been 
attributed to congenital infection with rubella
[165] or 
cytomegalovirus
[166-168]. Early postnatal oxygen 
deprivation in rats causes later autism-like behavior
[169]. 
A small group of children injured by perinatal hypoxia 
(and with selective limbic damage) developed severe 
infantile autism
[52]; one of Hans Asperger’s original Am. J. Biochem. & Biotech., 4 (2): 183-197, 2008 
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 patients, Hellmuth L, also endured perinatal hypoxia.  
  Later in infancy, brain insult does not generally 
seem to result in ASD-like conditions. In oncology 
referrals treated with anti-cancer therapy including 
ionizing radiation and chemotherapeutic agents, brain 
disturbances include epilepsy, attention and working 
memory deficits, intellectual impairment, and sensory 
perturbations including ocular and auditory problems, 
often with peripheral neuropathy
[170-173]. Full-blown 
ASD (fulfilling the diagnostic triad) is rare in survivors 
of anti-cancer therapy with the possible exception of 
younger children recovering after aggressive therapy of 
brain tumors (Wallace, H., pers comm). 
 
Identity of the environmental agent(s): It was 
suspected over many years that lead (Pb) poisoning 
might be associated with ASD
[174-181]; this has been 
confirmed in some specific cases
[182]. Attention has 
moved to organomercurials (notably methylmercury) 
found in some immunological reagents, because 
methylmercury (like TMT) can cause limbic damage in 
susceptible animal models
[183]. 
  Elevated body levels of heavy metals are reported 
in some ASD subjects
[174,175,184,185], with excess of 
mercury in early baby teeth
[186]. Urinary porphyrin 
levels (a marker of heavy metal toxicity) were 
significantly elevated in children with autistic 
disorder
[145]. Removal of heavy metals by chelation 
reduced urinary porphyrin levels
[145] pointing to, but not 
proving, a cause-effect relationship. A later report 
reiterated the porphyrin excess in ASD subjects
[187] but 
further work is required to confirm the generality of 
these observations. 
  Despite the focus on heavy metals, a combination 
of exposures is likely. Generally, a combination of 
agents can cause significant damage even when each is 
at sub-threshold or “safe” levels, exemplified by 
multiple xenoestrogen exposure
[188]. Environmental 
chemicals appear to synergize with heavy metals to 
increase the extent of damage produced
[189]: synergy 
between mercury and polychlorinated biphenyl toxicity 
has been reported in dual-exposed children
[190]. Specific 
evidence for chemical toxicity in ASD is provided by 
increased levels of trichloroethylene and toluene
[191], 
polychlorinated biphenyls and dioxins
[192], further 
underscored by evidence of genetic linkage to chemical 
detoxification gene alleles.  
 Though  local  atmospheric mercury correlates with 
ASD rates in Texas
[193], conjoint exposure emerged as a 
significant factor in the California association study - 
there was a 5-fold elevation in ASD rates in highest 
versus lowest exposure regions when overall exposure 
was considered (including heavy metals and chemical 
toxins)
[192]. The increased prevalence of ASD in urban 
versus rural areas
[193-195] supports this conclusion. 
 
Susceptibility to toxic damage: Deficits in 
detoxification may explain why only a proportion of 
children develop ASD. There is evidence of a heavy 
metal mobilization deficiency in affected children. Hair 
is a significant export route for mercury, but mercury 
was largely absent from first baby hair of children who 
went on to be diagnosed with ASD
[196]. Comparing 94 
ASD samples with 45 age-matched controls, mercury 
levels were over 7-fold higher in samples from control 
children. Levels of mercury varied inversely with 
severity of the disorder – the children with the least hair 
mercury were subsequently those most severely 
affected
[196]. Reduced metal levels in hair of ASD 
children have been confirmed
[197]. Children may be 
especially at risk if they are unable to mobilize 
organometals. 
 
Present versus historic exposure: 5% of inner-city 
minority children had unsuspected elevations of urinary 
mercury
[198] but the route of exposure is difficult to 
decipher. Early-life (gestation/lactation) exposure to 
mercury has been expressed as an algorithm of maternal 
dental amalgams, sea-food consumption, and a specific 
maternal immunoglobulin (rhoD or rhesus: generally 
administered at 27 weeks gestation) that contains a 
organomercury preservative
[196]. However, there are 
major complexities in evaluation. Metals, like lead and 
tin (but mercury less so), are deposited in bone over 
decades. During pregnancy and lactation, turnover of 
maternal bone supplies the unborn child and infant with 
minerals
[199]. 5-10% of maternal skeletal mineral is lost 
during lactation alone
[200]. If maternal heavy metal 
burden is significant, there will be toxic exposure of the 
unborn or breast-fed child
[201,202]. 
  Chemical exposure is also widespread
[203], with 
some alarmingly high levels in human organs
[204]. 
These agents accumulate with maternal age
[205,206], 
predominantly in fatty tissues. Maternal lipids, like 
metals and minerals, are passed to the child during 
gestation and lactation
[207]: mobilization of accumulated 
lipid-soluble residues is likely to contribute to early-life 
exposure. In support of a specific maternal contribution, 
ASD rates are elevated in the children of older 
mothers
[150,164,192,208] though other studies have queried 
this finding
[151,209]. The age-effect could relate to 
accumulated toxic exposure. An association with 
paternal age has also been reported
[210].  
  The possibility that ASD in offspring might result 
from accumulated toxicity over more than one 
generation is worthy of consideration. It is notable that Am. J. Biochem. & Biotech., 4 (2): 183-197, 2008 
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in fetal anticonvulsant syndrome (overlapping with 
ASD), a known genetic vulnerability (specific MTHFR 
alleles) was found in the mothers, but not in the 
affected children themselves
[211]. Indeed, parents of 
ASD children can themselves manifest behavioral 
idiosyncracies that fall short of meeting the diagnostic 
criteria of autism
[212,213], and which could be consistent 
with historic parental exposure. 
 
Two critical factors: environmental exposure and 
genetic susceptibility: It is argued that increasing ASD 
prevalence rates can be ascribed to early environmental 
toxic exposure, notably in utero, combined with genetic 
susceptibility and the regional sensitivity of the limbic 
brain. The “two-hit” model
[214] proposes that an 
external trigger factor must be combined with genetic 
predisposing factors to produce this disorder. The 
genetic factor may be in the child, for instance low-
activity alleles for key neurodevelopmental genes 
where environmental challenge can expose sub-clinical 
genetic deficiencies that culminate in new 
developmental phenotypes
[215,216]. Where susceptibility 
genes affect detoxification pathways the genetic factor 
may be in the mother as well as in the child. Further 
research is warranted to determine the precise identity 
of the specific environmental agents responsible
[217] in 
order to devise appropriate preventative/therapeutic 
interventions. 
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